Dementia and Alzheimer Disease

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 17, 2021.

The director of the division of vascular neurology at the University of Utah discussed ongoing efforts from the AAN, as well as the potential to integrate advanced practice providers into neurology teams.

The division chief of vascular neurology at the University of Utah discussed the misperceptions surrounding the field of neurology, as well as the importance of increasing fellowship training.

The division chief of vascular neurology at the University of Utah discussed the driving force behind the national shortage of neurologists and its effect on patient care.

Here's what is coming soon to NeurologyLive.

Jennifer Majersik, MD, MS, commented on how the AAN, as well as current neurologists and specialists, can help generate interest in the field of neurology to meet patient needs.

Jennifer Majersik, MD, MS, division chief of vascular neurology at the University of Utah, discussed contributing factors to the neurologist shortage, as well as ongoing efforts to increase interest in the field.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 10, 2021.

James E. Galvin, MD, MPH, provided thoughts on the struggles to raise dementia literacy and awareness in underserved, rural, ethnically diverse populations through the ongoing pandemic.

In addition to his work study pimavanserin in treating dementia-related psychosis, the director of the Banner Alzheimer’s Institute commented on the potential for aducanumab in Alzheimer disease.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive team.

The director of Banner Alzheimer’s Institute spoke on the importance of biomarkers in Alzheimer disease, as well as the ongoing improvements in digital technologies.

Following the COVID-19 pandemic, investigators are seeing a shift towards remote trials in an effort to avoid participants having to be in-person at a brick-and-mortar site.

Jacobo Mintzer, MD, MPA, discussed a wide range of Alzheimer disease related topics, including the use of methylphenidate, reactions to AAIC, and the aducanumab approval.

Here's what is coming soon to NeurologyLive.

Both short and long sleep durations were associated with worse self-reported cognitive function and multiple lifestyle outcomes, suggesting a U-shaped association.

Older adults with CI were found to require a significantly higher number of visits during home health care episodes, particularly skilled nursing visits.

Two study authors provide commentary on data that suggests that offering clinicians more perspective into the individual patient experience can help inform care for those individuals with DRP.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 3, 2021.

The director of the Banner Alzheimer’s Institute discussed areas of success and those facing challenges for Alzheimer disease clinical trials.

The director of the Alzheimer’s Prevention Clinic at Weill Cornell Medicine discussed the topics and ideas that clinicians should look forward to at the 2021 International Congress on the Future of Neurology.

The global head of Neurodegeneration at Roche/Genentech offered her insights on additional analysis of the DIAN-TU trial of gantenerumab and perspectives on biomarker data.

The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine discussed the current understanding of COVID-19 and its associations with cognitive decline and Alzheimer disease.

AC Immune and Genentech announced that treatment with semorinemab, an investigational antitau antibody, in the phase 2 LAURIET study resulted in significant changes from baseline on ADAS-Cog11 scores.